Ann Pediatr Endocrinol Metab.  2013 Mar;18(1):1-8. 10.6065/apem.2013.18.1.1.

The current state of dyslipidemia in Korean children and adolescents and its management in clinical practice

• Lim JS

• KMID: 1429671
• DOI: http://doi.org/10.6065/apem.2013.18.1.1

Abstract

Cardiovascular disease (CVD) is a leading cause of death worldwide including Korea. The risk factors of CVD are known as positive family history of early CVD, obesity, hypertension, diabetes, and dyslipidemia. Among those, dyslipidemia is one of modifiable risk factors. Dyslipidemia starts in childhood and progress to adulthood. Furthermore, dyslipidemia cause atherosclerosis and is closely related to other CVD risks. On the rationale that early identification and control of pediatric dyslipidemia will reduce the risk and severity of CVD in adulthood, the National Heart, Lung, and Blood Institute guidelines expanded to universal screening for lipid levels. However, there was no guideline for lipid screening and management in Korean children and adolescents yet. This review deals with the rationale of early identification and control of pediatric dyslipidemia along with the current Korean status of pediatric dyslipidemia. This review also deals with how to screen, diagnosis, and treatment of pediatric dyslipidemia.

Keyword

Dyslipidemia; Children; Adolescents; Screening; Management

MeSH Terms

Adolescent
Atherosclerosis
Cardiovascular Diseases
Cause of Death
Child
Collodion
Dyslipidemias
Humans
Hypertension
Korea
Mass Screening
National Heart, Lung, and Blood Institute (U.S.)
Obesity
Risk Factors
Collodion

Figure

• 

  Fig. 1 Diagnostic and therapeutic algorithm for children and adolescents with elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG). TC, total cholesterol; FHx, family history; RFs, risk factors; FLP, fasting lipid profile; DM, diabetes mellitus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CVD, cardiovascular disease.

Reference

1. World Health Organization (WHO). The global burden of disease: 2004 update [Internet]. Geneva: WHO;c2013. cited 2013 Jan 15. Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.

2. Statistics Korea. Annual report on the cause of death statistics, 2010 [Internet]. Daejeon: Statistics Korea;2013 Jan 9. Available from: http://kostat.go.kr/portal/english/news/1/8/index.board?bmode=read&bSeq=&aSeq=250427&pageNo=1&rowNum=10&navCount=10&currPg=&sTarget=title.

3. Lee MH, Kim HC, Ahn SV, Hur NW, Choi DP, Park CG, et al. Prevalence of dyslipidemia among Korean adults: Korea National Health and Nutrition Survey 1998-2005. Diabetes Metab J. 2012; 36:43–55. PMID: 22363921.

4. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011; 128(Suppl 5):S213–S256. PMID: 22084329.

5. Daniels SR, Greer FR. Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008; 122:198–208. PMID: 18596007.

6. Kwiterovich PO Jr. Recognition and management of dyslipidemia in children and adolescents. J Clin Endocrinol Metab. 2008; 93:4200–4209. PMID: 18697860.

7. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992; 89:495–501. PMID: 1741227.

8. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K, et al. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation. 2003; 107:1562–1566. PMID: 12654618.

9. McGill HC Jr, McMahan CA, Zieske AW, Malcom GT, Tracy RE, Strong JP. Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation. 2001; 103:1546–1550. PMID: 11257083.

10. McGill HC Jr, McMahan CA, Zieske AW, Sloop GD, Walcott JV, Troxclair DA, et al. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. Arterioscler Thromb Vasc Biol. 2000; 20:1998–2004. PMID: 10938023.

11. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. The Bogalusa Heart Study. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 1998; 338:1650–1656. PMID: 9614255.

12. Li S, Chen W, Srinivasan SR, Bond MG, Tang R, Urbina EM, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA. 2003; 290:2271–2276. PMID: 14600185.

13. Juonala M, Viikari JS, Ronnemaa T, Marniemi J, Jula A, Loo BM, et al. Associations of dyslipidemias from childhood to adulthood with carotid intima-media thickness, elasticity, and brachial flow-mediated dilatation in adulthood: the Cardiovascular Risk in Young Finns Study. Arterioscler Thromb Vasc Biol. 2008; 28:1012–1017. PMID: 18309111.

14. Bao W, Srinivasan SR, Wattigney WA, Bao W, Berenson GS. The Bogalusa Heart Study. Usefulness of childhood low-density lipoprotein cholesterol level in predicting adult dyslipidemia and other cardiovascular risks. Arch Intern Med. 1996; 156:1315–1320. PMID: 8651840.

15. Christensen B, Glueck C, Kwiterovich P, Degroot I, Chase G, Heiss G, et al. Plasma cholesterol and triglyceride distributions in 13,665 children and adolescents: the Prevalence Study of the Lipid Research Clinics Program. Pediatr Res. 1980; 14:194–202. PMID: 6966785.

16. Hickman TB, Briefel RR, Carroll MD, Rifkind BM, Cleeman JI, Maurer KR, et al. Distributions and trends of serum lipid levels among United States children and adolescents ages 4-19 years: data from the Third National Health and Nutrition Examination Survey. Prev Med. 1998; 27:879–890. PMID: 9922071.

17. Yang S, Hwang JS, Park HK, Lee HS, Kim HS, Kim EY, et al. Serum lipid concentrations, prevalence of dyslipidemia, and percentage eligible for pharmacological treatment of Korean children and adolescents; data from the Korea National Health and Nutrition Examination Survey IV (2007-2009). PLoS One. 2012; 7:e49253. PMID: 23251338.

18. Ford ES, Li C, Zhao G, Mokdad AH. Concentrations of low-density lipoprotein cholesterol and total cholesterol among children and adolescents in the United States. Circulation. 2009; 119:1108–1115. PMID: 19221218.

19. Kim SH, Ahn BC, Joung H, Park MJ. Lipid profiles and prevalence of dyslipidemia in Korean adolescents. Endocrinol Metab. 2012; 27:208–216.

20. Centers for Disease Control and Prevention (CDC). Prevalence of abnormal lipid levels among youths: United States, 1999-2006. MMWR Morb Mortal Wkly Rep. 2010; 59:29–33. PMID: 20094024.

21. Lim S, Jang HC, Park KS, Cho SI, Lee MG, Joung H, et al. Changes in metabolic syndrome in American and Korean youth, 1997-2008. Pediatrics. 2013; 131:e214–e222. PMID: 23209102.

22. Kit BK, Carroll MD, Lacher DA, Sorlie PD, DeJesus JM, Ogden C. Trends in serum lipids among US youths aged 6 to 19 years, 1988-2010. JAMA. 2012; 308:591–600. PMID: 22871871.

23. Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, et al. The metabolic syndrome in children and adolescents: an IDF consensus report. Pediatr Diabetes. 2007; 8:299–306. PMID: 17850473.

24. McBride PE. Triglycerides and risk for coronary heart disease. JAMA. 2007; 298:336–338. PMID: 17635897.

25. Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004; 110:2678–2686. PMID: 15492305.

26. Ritchie SK, Murphy EC, Ice C, Cottrell LA, Minor V, Elliott E, et al. Universal versus targeted blood cholesterol screening among youth: The CARDIAC project. Pediatrics. 2010; 126:260–265. PMID: 20624798.

27. Haney EM, Huffman LH, Bougatsos C, Freeman M, Fu R, Steiner RD, et al. Screening for lipid disorders in children and adolescents [Internet]. Rockville: Agency for Healthcare Research and Quality;2007. cited 2013 Jan 17. Available from: http://www.ncbi.nlm.nih.gov/books/NBK33480/.

28. US Preventive Services Task Force. Screening for lipid disorders in children: US Preventive Services Task Force recommendation statement. Pediatrics. 2007; 120:e215–e219. PMID: 17606545.

29. Yu HH, Markowitz R, De Ferranti SD, Neufeld EJ, Farrow G, Bernstein HH, et al. Direct measurement of LDL-C in children: performance of two surfactant-based methods in a general pediatric population. Clin Biochem. 2000; 33:89–95. PMID: 10751585.

30. Srinivasan SR, Frontini MG, Xu J, Berenson GS. Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa Heart Study. Pediatrics. 2006; 118:201–206. PMID: 16818566.

31. Lee KH, Son CS, Lee JW, Tockgo YC. Serum lipids in children and adolescents with family history of coronary artery diseases. J Korean Pediatr Soc. 1995; 38:482–492.

32. Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. J Cardiovasc Nurs. 2007; 22:218–253. PMID: 17545824.

33. Korea Education Development Institute. School health medical examination guideline [Internet]. Seoul: Ministry of Education, Science, and Technology;2008. cited 2012 Feb 6. Available from: http://www.keric.net/keric/search/SearchControler.jsp?menuchk=yes&mode=1&menuon=22&sortItem=item_pubyear&pg=6.

34. Rainwater DL, McMahan CA, Malcom GT, Scheer WD, Roheim PS, McGill HC Jr, et al. The PDAY Research Group. Lipid and apolipoprotein predictors of atherosclerosis in youth: apolipoprotein concentrations do not materially improve prediction of arterial lesions in PDAY subjects. Arterioscler Thromb Vasc Biol. 1999; 19:753–761. PMID: 10073983.

35. Manlhiot C, Larsson P, Gurofsky RC, Smith RW, Fillingham C, Clarizia NA, et al. Spectrum and management of hypertriglyceridemia among children in clinical practice. Pediatrics. 2009; 123:458–465. PMID: 19171610.

36. Gidding SS, Dennison BA, Birch LL, Daniels SR, Gillman MW, Lichtenstein AH, et al. Dietary recommendations for children and adolescents: a guide for practitioners: consensus statement from the American Heart Association. Circulation. 2005; 112:2061–2075. PMID: 16186441.

37. Tammi A, Ronnemaa T, Miettinen TA, Gylling H, Rask-Nissila L, Viikari J, et al. Special Turku Coronary Risk Factor Intervention Project. Effects of gender, apolipoprotein E phenotype and cholesterol-lowering by plant stanol esters in children: the STRIP study. Acta Paediatr. 2002; 91:1155–1162. PMID: 12463311.

38. Laurin D, Jacques H, Moorjani S, Steinke FH, Gagne C, Brun D, et al. Effects of a soy-protein beverage on plasma lipoproteins in children with familial hypercholesterolemia. Am J Clin Nutr. 1991; 54:98–103. PMID: 2058593.

39. Engler MM, Engler MB, Malloy MJ, Paul SM, Kulkarni KR, Mietus-Snyder ML. Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study). Am J Cardiol. 2005; 95:869–871. PMID: 15781019.

40. Hong HR, Kim SU, Kang HS. Physical activity and metabolic syndrome in Korean children. Int J Sports Med. 2009; 30:677–683. PMID: 19569013.

41. Shin KO, Oh SY, Park HS. Empirically derived major dietary patterns and their associations with overweight in Korean preschool children. Br J Nutr. 2007; 98:416–421. PMID: 17433127.

42. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, et al. American Heart Association Writing Group. Summary of the American Heart Association's scientific statement on drug therapy of high-risk lipid abnormalities in children and adolescents. Arterioscler Thromb Vasc Biol. 2007; 27:982–985. PMID: 17442893.

43. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004; 292:331–337. PMID: 15265847.

44. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003; 143:74–80. PMID: 12915827.

45. de Jongh S, Ose L, Szamosi T, Gagne C, Lambert M, Scott R, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation. 2002; 106:2231–2237. PMID: 12390953.

46. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr. 1996; 129:42–49. PMID: 8757561.

47. Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin. 2007; 23:767–775. PMID: 17407633.